GLP-1 cardiometabolic expansion market seen reaching $101.82 billion by 2030

The Business Research Company says the GLP-1 cardiometabolic expansion market will grow from $51.8 billion in 2025 to $101.82 billion by 2030, driven by broader use beyond diabetes and rising obesity and diabetes rates. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - GLP-1 drugs are moving from a diabetes-focused category into broader cardiometabolic care, which could expand use across obesity, cardiovascular disease and chronic kidney disease. - The market’s projected jump to $101.82 billion by 2030 signals continued demand for therapies that address multiple chronic conditions at once. - Rising obesity and diabetes rates are increasing the need for treatments that improve glycemic control, support weight loss and reduce related health risks.

What happened: - The Business Research Company released a report on the GLP-1 cardiometabolic expansion market on Sept. 9, 2026. - The report values the market at $59.47 billion in 2026, up from $51.8 billion in 2025. - The report forecasts the market will reach $101.82 billion by 2030. - The company projects a 14.4% compound annual growth rate from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region through the forecast period.

The details: - GLP-1 cardiometabolic expansion refers to therapies targeting the GLP-1 pathway being used for a wider range of cardiometabolic health issues beyond their original metabolic focus. - The report ties historical growth to rising type 2 diabetes cases, higher obesity rates, early GLP-1 receptor agonist development, greater awareness of metabolic syndrome and expanded endocrinology guidelines. - The forecast period is being shaped by broader use beyond diabetes, increased adoption of combination incretin treatments and more preventive cardiology use. - The report also points to greater focus on obesity-related comorbidities and precision medicine in metabolic disease management. - Emerging trends include GLP-1 use in cardiovascular disease and chronic kidney disease management. - Other trends include combination therapies that target multiple cardiometabolic pathways, obesity-related risk reduction programs and digital chronic disease management platforms. - The report’s regional coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report offers market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies analysis and future trend analysis. - The company said it also updated graphics and tables for the 2026 market reports. - The report provides a free sample at the sample request page. - The full report is available here.

Between the lines: - The forecast suggests GLP-1 therapies are becoming a platform category rather than a single-indication drug class. - Public-health pressure from obesity and diabetes is helping justify broader use cases and deeper commercial investment. - The report’s emphasis on combination treatments and digital platforms points to a market that is shifting from standalone drugs to integrated care models. - CDC data cited in the release said 23 U.S. states had adult obesity rates above 35% in 2023, up from 22 states in 2022.

What's next: - The market is expected to keep expanding as evidence builds for GLP-1 use in cardiometabolic disease management. - Wider adoption of combination incretin treatments and preventive cardiology applications may shape the next phase of growth. - Asia-Pacific may narrow the gap with North America if healthcare investment and access continue to rise.

The bottom line: - GLP-1 therapies are expanding beyond diabetes, and the market data points to sustained double-digit growth through 2030.